Ticagrelor

In the US, Ticagrelor (ticagrelor systemic) is a member of the drug class platelet aggregation inhibitors and is used to treat Acute Coronary Syndrome.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

B01AC24

CAS registry number (Chemical Abstracts Service)

0274693-27-5

Chemical Formula

C23-H28-F2-N6-O4-S

Molecular Weight

522

Therapeutic Category

Antiplatelet agent inhibiting adenosine diphosphate-mediated platelet aggregation

Chemical Names

(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (USAN)

(1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (WHO)

1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)- (USAN)

Foreign Names

  • Ticagrelorum (Latin)
  • Ticagrelor (German)
  • Ticagrélor (French)
  • Ticagrelor (Spanish)

Generic Names

  • Ticagrelor (OS: BAN)
  • AR-C126532XX (IS)
  • AZD6140 (IS)
  • UNII-GLH0314RVC (IS)

Brand Names

  • Brilinta
    AstraZeneca, Canada; AstraZeneca, United States
  • Brilique
    AstraZeneca, Switzerland; AstraZeneca, Germany; AstraZeneca, France; AstraZeneca, Sweden; AstraZeneca, Austria; AstraZeneca, Bosnia & Herzegowina; AstraZeneca, Spain; AstraZeneca, United Kingdom; AstraZeneca, Netherlands; AstraZeneca, Norway
  • Possia
    AstraZeneca, Netherlands

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide
(web1)